These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 30445253)

  • 21. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
    Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
    J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hyaluronic acid-capped compact silica-supported mesoporous titania nanoparticles for ligand-directed delivery of doxorubicin.
    Gupta B; Poudel BK; Ruttala HB; Regmi S; Pathak S; Gautam M; Jin SG; Jeong JH; Choi HG; Ku SK; Yong CS; Kim JO
    Acta Biomater; 2018 Oct; 80():364-377. PubMed ID: 30201431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chitosan oligosaccharide-arachidic acid-based nanoparticles for anti-cancer drug delivery.
    Termsarasab U; Cho HJ; Kim DH; Chong S; Chung SJ; Shim CK; Moon HT; Kim DD
    Int J Pharm; 2013 Jan; 441(1-2):373-80. PubMed ID: 23174411
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mitochondrial Targeted Doxorubicin-Triphenylphosphonium Delivered by Hyaluronic Acid Modified and pH Responsive Nanocarriers to Breast Tumor: in Vitro and in Vivo Studies.
    Liu HN; Guo NN; Wang TT; Guo WW; Lin MT; Huang-Fu MY; Vakili MR; Xu WH; Chen JJ; Wei QC; Han M; Lavasanifar A; Gao JQ
    Mol Pharm; 2018 Mar; 15(3):882-891. PubMed ID: 29357260
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peptide dendrimer-Doxorubicin conjugate-based nanoparticles as an enzyme-responsive drug delivery system for cancer therapy.
    Zhang C; Pan D; Luo K; She W; Guo C; Yang Y; Gu Z
    Adv Healthc Mater; 2014 Aug; 3(8):1299-308. PubMed ID: 24706635
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Doxorubicin-loaded amphiphilic polypeptide-based nanoparticles as an efficient drug delivery system for cancer therapy.
    Lv S; Li M; Tang Z; Song W; Sun H; Liu H; Chen X
    Acta Biomater; 2013 Dec; 9(12):9330-42. PubMed ID: 23958784
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparative study of folate receptor-targeted doxorubicin delivery systems: dosing regimens and therapeutic index.
    Scomparin A; Salmaso S; Eldar-Boock A; Ben-Shushan D; Ferber S; Tiram G; Shmeeda H; Landa-Rouben N; Leor J; Caliceti P; Gabizon A; Satchi-Fainaro R
    J Control Release; 2015 Jun; 208():106-20. PubMed ID: 25869964
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bacterial cellulose hydrogel loaded with lipid nanoparticles for localized cancer treatment.
    Cacicedo ML; Islan GA; León IE; Álvarez VA; Chourpa I; Allard-Vannier E; García-Aranda N; Díaz-Riascos ZV; Fernández Y; Schwartz S; Abasolo I; Castro GR
    Colloids Surf B Biointerfaces; 2018 Oct; 170():596-608. PubMed ID: 29975908
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multifunctional DNA-gold nanoparticles for targeted doxorubicin delivery.
    Alexander CM; Hamner KL; Maye MM; Dabrowiak JC
    Bioconjug Chem; 2014 Jul; 25(7):1261-71. PubMed ID: 24911830
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Uptake and release profiles of PEGylated liposomal doxorubicin nanoparticles: A comprehensive picture based on separate determination of encapsulated and total drug concentrations in tissues of tumor-bearing mice.
    Wang H; Zheng M; Gao J; Wang J; Zhang Q; Fawcett JP; He Y; Gu J
    Talanta; 2020 Feb; 208():120358. PubMed ID: 31816795
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hyaluronic acid modified pH-sensitive liposomes for targeted intracellular delivery of doxorubicin.
    Paliwal SR; Paliwal R; Agrawal GP; Vyas SP
    J Liposome Res; 2016 Dec; 26(4):276-87. PubMed ID: 26784587
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Visual targeted therapy of hepatic cancer using homing peptide modified calcium phosphate nanoparticles loading doxorubicin guided by T1 weighted MRI.
    Zhang NN; Yu RS; Xu M; Cheng XY; Chen CM; Xu XL; Lu CY; Lu KJ; Chen MJ; Zhu ML; Weng QY; Hui JG; Zhang Q; Du YZ; Ji JS
    Nanomedicine; 2018 Oct; 14(7):2167-2178. PubMed ID: 30017962
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combining Tumor Microenvironment Modulating Nanoparticles with Doxorubicin to Enhance Chemotherapeutic Efficacy and Boost Antitumor Immunity.
    Amini MA; Abbasi AZ; Cai P; Lip H; Gordijo CR; Li J; Chen B; Zhang L; Rauth AM; Wu XY
    J Natl Cancer Inst; 2019 Apr; 111(4):399-408. PubMed ID: 30239773
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nanometronomic treatment of 4T1 breast cancer with nanocaged doxorubicin prevents drug resistance and circumvents cardiotoxicity.
    Mazzucchelli S; Bellini M; Fiandra L; Truffi M; Rizzuto MA; Sorrentino L; Longhi E; Nebuloni M; Prosperi D; Corsi F
    Oncotarget; 2017 Jan; 8(5):8383-8396. PubMed ID: 28039473
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles.
    Wu Y; Zhang Y; Zhang W; Sun C; Wu J; Tang J
    Colloids Surf B Biointerfaces; 2016 Feb; 138():60-9. PubMed ID: 26655793
    [TBL] [Abstract][Full Text] [Related]  

  • 36. (-)-Epigallocatechin-3-gallate alleviates doxorubicin-induced cardiotoxicity in sarcoma 180 tumor-bearing mice.
    Yao YF; Liu X; Li WJ; Shi ZW; Yan YX; Wang LF; Chen M; Xie MY
    Life Sci; 2017 Jul; 180():151-159. PubMed ID: 27956351
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Possible contribution of sialic acid to the enhanced tumor targeting efficiency of nanoparticles engineered with doxorubicin.
    Lee SY; Nam S; Koo JS; Kim S; Yang M; Jeong DI; Hwang C; Park J; Cho HJ
    Sci Rep; 2020 Nov; 10(1):19738. PubMed ID: 33184416
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Redox-responsive mesoporous selenium delivery of doxorubicin targets MCF-7 cells and synergistically enhances its anti-tumor activity.
    Zhao S; Yu Q; Pan J; Zhou Y; Cao C; Ouyang JM; Liu J
    Acta Biomater; 2017 May; 54():294-306. PubMed ID: 28267598
    [TBL] [Abstract][Full Text] [Related]  

  • 39. pH-Triggered Surface Charge Reversed Nanoparticle with Active Targeting To Enhance the Antitumor Activity of Doxorubicin.
    Du JB; Cheng Y; Teng ZH; Huan ML; Liu M; Cui H; Zhang BL; Zhou SY
    Mol Pharm; 2016 May; 13(5):1711-22. PubMed ID: 26998644
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Folate-mediated mitochondrial targeting with doxorubicin-polyrotaxane nanoparticles overcomes multidrug resistance.
    Wang H; Yin H; Yan F; Sun M; Du L; Peng W; Li Q; Feng Y; Zhou Y
    Oncotarget; 2015 Feb; 6(5):2827-42. PubMed ID: 25605018
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.